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Background: Lapatinib alone or in combination with other agents, mostly capecitabine is used for patients with advanced/meta-
static HER2 positive breast cancer (HER2+BC) after progression on trastuzumab based therapy. Here we report our experience 
with lapatinib based therapy in this setting. Material and Methods: 67 consecutive patients received lapatinib based therapy. 
58 (86.6%) received lapatinib + capecitabine (LC), 7 (10.4%) with other agents and 2 (3.0%) as single agent lapatinib. Data was 
collected from patients’ records retrospectively. Results: Objective response to lapatinib based therapy in 64 evaluable patients was 
64.0% in all patients and 64.0% in patients who received LC. Median progression free survival and overall survival were 10 and 
27 months in all patients and 10 and 17 months in patients who received LC, respectively. 16 (24.0%) patients had dose delay 
> 1 week and/or dose reduction. Conclusion: Lapatinib based therapy is an effective treatment for women with advanced/meta-
static HER2+BC after prior exposure to trastuzumab. It yields meaningful response rates, progression free and overall survival. 
Some patients require dose adjustments.
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The human epidermal growth factor recep-
tor 2 (EGFR2 or HER2 or Erb-B2) is a member 
of the EGFR family of tyrosine kinase receptors. 
HER2 is a proto-oncogene located at the long arm 
of human chromosome 17 and is overexpressed 
in 15–30% of breast cancers (BC). It plays an important 
role in the development and progression of cancer and 
is strongly associated with disease recurrence and 
poor prognosis [1, 2]. Clinical research over the recent 
2 decades contributed successfully to the develop-
ment drugs that specifically target HER2 receptors. 
Trastuzumab (T), a monoclonal antibody that binds 
to extracellular domain of the receptor improves 
the outcome of patients with HER2 positive breast 
cancer (HER2+BC) and is licensed for the use in early 
and advanced/metastatic HER2+ breast cancer (A/
MHER2+BC) [3, 4]. When tumour cells eventually 
develop resistance to T, further inhibition of HER2 re-
ceptor signaling is needed to overcome this escape. 
Lapatinib (L) is an orally active small molecule that 
inhibits the tyrosine kinases of HER2 and EGFR 
(HER1). In 2007, the American Food and Drug Admini-
stration (FDA) licensed L for use in combination with 
capecitabine (C) in the treatment of patients with A/
MHER2+BC who had received prior therapy including T. 
This approval was based on the results of a randomi-
zed phase III trial showing a longer time to progression 
in favor of the group receiving L [5]. Subsequent clini-
cal trials confirmed the efficacy of single agent L and 
L in combination with other anti-cancer agents inclu-
ding letrozole, anastrazole, T and a number of other 
chemotherapeutic agents [6–9]. Most of the available 
research studied lapatinib-based therapy (LBT) in pa-
tients from western countries. However, LBT is used 
all over the world for women with A/MHER2+BC. There 
is scarcity of data on efficacy and tolerability in these 
women and certainly in women from Arabic ethnicity.
Here we retrospectively report our experience with 
LBT in women with A/MHER2+BC treated in 5 different 
oncology units in Western region of Saudi Arabia.
MATERIALS AND METHODS
All consecutive patients who started LBT for 
A/MHER2+BC between February 2008 and June 
2013 were eligible for inclusion in the study. LBT was 
identified as single agent L or L in combination with 
any anti-cancer hormonal therapy or chemotherapy. 
72 patients met the eligibility criteria. However, 
the medical records of 5 patients were unobtainable 
or contained inadequate information. Adequate clinical 
data was available for 67 patients and are the subject 
of this report. 58/67 (86.6%) received lapatinib plus 
capecitabine (LC).
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Starting dose of L was 1250 mg daily and 
of C 1000 mg/m2 twice a day on days 1–14 every 
3 weeks. Data was collected from patients’ paper and 
electronic records retrospectively by the treating medi-
cal oncologists. Progression free survival (PFS) was 
defined as time from starting LBT until first evidence 
of radiological or obvious clinical progression or last 
follow up. Overall survival (OS) was defined as time 
from starting LBT until death or last follow up.
Radiological imaging and/or reports were reviewed 
by the treating medical oncologists to document re-
sponse and progression. Central radiology review was 
not obtained. Response Evaluation Criteria in Solid 
Tumors (RECIST) were used to guide response assess-
ment. During LBT, patient follow up generally consisted 
of regular physical examination and relevant hemato-
logical and biochemical laboratory assessment every 
3 weeks. Radiological response assessment did not 
follow a predefined protocol. Instead it was carried out 
according to clinical impression and physicians’ discre-
tion. However, generally most patients had radiological 
assessment every 2–3 months mostly by CT scan.
Due to retrospective nature of the study and con-
cerns about incomplete documentation of toxicity 
data in patients’ records, surrogates for toxicity and 
tolerability was used. These surrogates were dose de-
lay for > 1 week (including discontinuation) and dose 
reduction in any component of the regimen.
Statistical analysis was performed using SPSS 
11.5 for Windows. Response rate was expressed 
a percentage of evaluable patients. PFS and OS were 
calculated using life tables and Kaplan — Meier estima-
tor. Institutional review board approval was granted for 
this study.
RESULTS
Patients’ characteristics including disease and 
treatment information prior to administration of LBT 
are depicted in Table 1. Thirty eight (57.0%) patients 
received adjuvant chemotherapy and 26 of them 
(68.0%) received adjuvant T based chemotherapy. 
Median disease free survival was 22 (0–120) months. 
All except 4 patients received T either in the adjuvant 
(n = 26) or palliative (n = 57) settings. Two of these 4 pa-
tients presented with stage III disease, refused adjuvant 
chemotherapy and received adjuvant hormonal therapy. 
The other 2 patients presented with stage IV disease 
at initial diagnosis, refused palliative intravenous treat-
ment and received first line palliative hormonal therapy.
L was combined with C in 58 (86.6%) patients 
while 9 (13.4%) patients received either L in combi-
nation with other agents or as a single anti-cancer 
treatment (see Table 1). In 9/67 (13.4%) patients LBT 
was the first line of treatment for A/MHER2+BC. Six 
of these 9 patients received adjuvant chemotherapy 
and T prior to development of advanced disease. 
The other 3 patients were never exposed to T as they 
refused intravenous treatment and received first line 
palliative L combined with C, letrozole and exemestane 
(1 in each patient). Dose delay for > 1 week or discon-
tinuation due to to xicity was reported in 13 (19.4%) 
and dose reduction in 9 (13.4%) patients. Sixteen pa-
tients (24.0%) had dose delay > 1 week and/or dose 
reduction.
Table 1. Patients’ characteristics
Characteristics Number of pa-tients, n (%)
Stage at primary diagnosis (n = 67):
I
II
III
IV
1 (1.5)
12 (17.9)
35 (52.2)
19 (28.4)
Estrogen and/or progesterone receptors (n = 67):
Positive
Negative
Unknown
33 (49.0)
33 (49.0)
1 (2.0)
Adjuvant chemotherapy (n = 67):
No
Yes:
T based
non-T based
29 (43.0)
38 (57.0)
26 (68.0)
12 (32.0)
Disease free survival Median = 22  
(0–120) months
Lines of palliative chemotherapy prior to L (n = 67):
None
One line
Two lines
Three lines
9 (13.4)
37 (55.2)
15 (22.4)
6 (9.0)
Palliative chemotherapy prior to L (n = 67):
T based (n = 58)
non-T based (n = 58)
58 (86.6)
57 (98.0)
1 (2.0)
Age at start of L Median = 
46 (22–70) years
L based regimens (n = 67):
LC
L and letrozole
L and exemestane
Single agent L
L and T
L and vinorelbine (LV)
58 (86.6)
3 (4.5)
2 (3.0)
2 (3.0)
1 (1.5)
1 (1.5)
3 patients were not evaluable for response. Objec-
tive response in evaluable patients was 41/64 (64.0%) 
patients in all patients, 36/56 (64.0%) in patients who 
received LC and 5/8 (62.5%) in patients who received 
other LBT regimens. Detailed response to treatment 
is depicted in Table 2.
Table 2. Response to LBT
Variables All patients, n (%) LC regimen,  n (%)
Other regimens, 
n (%)
Total number 67 58 9
Evaluable for re-
sponse
64 56 8
CR 5 (8.0) 5 (9.0) 0 (0.0)
PR 36 (56.0) 31 (55.0) 5 (62.5)
Objective re-
sponse
(CR + PR)
41 (64.0) 36 (64.0) 5 (62.5)
SD 11 (17.0) 10 (18.0) 1 (12.5)
PD 12 (19.0) 10 (18.0) 2 (25.0)
Note: CR — complete response; PR — partial response; SD — stable disease; 
PD —progressive disease.
After a median follow up of 18 (4–38) months, the me-
dian PFS was 10 months (95% CI: 7.8–12.2) (Fig. 1). Me-
dian OS was 27 months (95% CI: 12.13–41.87) (Fig. 2).
At time of analysis (October 2013), 26 (39.0%) 
patients were still continuing LBT while 41 (61.0%) 
stopped this treatment due to progressive disease 
(n = 36), toxicity (n = 2) and lost to follow up (n = 3). 
20 (30.0%) patients received at least one subsequent 
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line of chemotherapy yielding objective response 
in 36.0% of evaluable patients.
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Fig. 1. PFS of all patients (n = 67)
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Fig. 2. OS of all patients (n = 67)
DISCUSSION
LC is an established systemic treatment for patients 
with A/MHER2+BC who received prior therapy inclu-
ding T. The rational for this treatment are the results 
of the landmark registration phase III that randomized 
patients to single agent C or LC. Median time to progres-
sion in was 8.4 months in LC group and 4.4 in C group 
(HR 0.49; 95% CI: 0.34–0.71; p < 0.001) [5].
There are some similarities and differences between 
our patients and patients included in the registration 
trial. The differences can be explained by the strict 
prespecified patients’ selection in prospective research 
setting and the relatively flexible approach in daily real 
life practice. For example, in the registration trial all pa-
tients received prior T in adjuvant (5.0%) or metastatic 
(95.0%) settings. However, in our study 4 (6.0%) pa-
tients have never received prior T due to patients’ own 
choice. Another possible reason for differences is varia-
tions in social and disease characteristics among both 
studies population. For example, in registration trial, 
the median age was 51 and 54 years in each treatment 
arm and was 46 years in our population. This reflects 
the Saudi Arabian community young age distribution 
where only 5% of the whole population are 60 years 
or older according to the year 2013 United Nations 
report [10].
In addition, some reports show that women from 
the Middle East develop BC at relatively younger 
age. Age at diagnosis of BC was < 45 years in 49% 
of 6922 women with BC in an epidemiological study 
from Saudi Arabia [11]. Previous work by our group 
reported that median age of women with HER2+BC was 
45 years [2]. Despite these minor differences, our 
patients generally represent HER2+BC population. 
For example, 49.0% of our patients have hormone 
receptor positive disease which is similar to 48.0% 
in the registration trial, 50.0% in the adjuvant HERA 
phase III international study and 50% in a previous 
work by our group [2–4].
Objective response to LC in our patient was 64.0%. 
This is higher than what was reported in the registration 
trial (22.0%). Possible explanation include (a) assess-
ment was performed by reviewing imaging and/or reports 
by the treating medical oncologists and not by a radio-
logist (b) a radiology report may describe a response 
while tumor shrinkage is less than needed for accurate 
definition of response and thus overestimate response 
rates (c) small number of patients in our study. It is well 
recognized that response rates are usually higher 
in retrospective and in smaller than larger studies. 
Response to LC was 34; 41; 43 and 44% in 4 different 
studies each recruited 26; 116; 68 and 52 patients, 
respectively [12–15].
It is reassuring that response was also seen in 5 out 
of 9 patients who received either L in combination with 
other agents or as a single anti-cancer treatment. 
Ad ding L to chemotherapy has proven to improve 
outcome in clinical trial. For example L improved re-
sponse rate (69 vs. 50%), PFS (9.7 vs. 6.5 months) and 
OS (27.8 vs. 20.5 months) when added to paclitaxel 
compared to paclitaxel alone [16]. Similar results were 
reported in the subset of patients with HER2 overex-
pressed disease from another trial [17]. Response 
to combined L and vinorelbine (LV) is reported in 31 and 
14% of patients in phase I and single arm phase II tri-
als [18, 19]. A phase II study randomized 37 patients 
to LC and 75 patients — to LV. Response rates were 
35% in LC and 20% in LV arms. Median PFS was 
6.2 in both arms. Median OS was 19.4 months in LC and 
24.3 months in LV arms (HR 1.02; 95% CI 0.50–2.06). 
These results indicate that LV offers an effective treat-
ment option that is comparable LC [20].
Adding L the hormonal therapy letrozole has also 
proven to improve outcome in these patients com-
pared to hormonal therapy alone [21, 22]. Only one 
of our patients received L combined with T (LT). She 
achieved partial response and PFS of 7 months.
The prospect of dual HER2 blockage is intriguing 
form the efficacy point of view but also as a non-
chemotherapy combination. A phase III trial randomi-
zed patients with A/MHER2+BC after progression 
on T to single agent L or LT. Response were achieved 
in 7 and 10% and Clinical benefit in 12 and 25% 
in L and LT arms, respectively [8]. Updated final 
analysis confirmed superiority LT in PFS (HR 0.74; 
95% CI 0.58–0.94; p = 0.011) and in OS benefit 
(HR 0.74; 95% CI 0.57–0.97; p = 0.026) despite 
the crossover of 52% of patients from L arm to receive 
subsequent T [23]. Response rate of 8.0% and clinical 
benefit rate of 14.1% were reported in a phase II trial 
of single agent L [6]. Two of our patients received sin-
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gle agent L. Both of them achieved objective response. 
PFS and OS were of 14 and 15 months for one patient 
and 7 and 10 months of the other. Both did not receive 
any subsequent anti-cancer therapy. After a median 
follow up of 18 (4–38) months, the median PFS was 
10 months in all patients and 10 months in 58 patients 
who received LC. This is in line with the PFS duration 
of 8.4 months reported in the LC arm of the registra-
tion trial [5]. Median OS was 27 months in all patients 
and 17 months in patients who received LC. This 
is exactly the same median OS of 75 weeks (equiva-
lent to 17 months) reported in LC arm at the updated 
analysis of the registration trial [24].
In the registration phase III trial, most adverse 
events in LC arm were of grades I and II. Grade III 
serious adverse events were diarrhea (12.0%) and 
hand foot syndrome (7.0%) while other grade III 
adverse events were reported in ≤ 2% of patients. 
Only 2 patients developed grade IV toxicity. Adverse 
events led to discontinuation of treatment in 22 pa-
tients in LC arm [5]. Detailed documentation of toxi-
city in the context of a clinical study is a predefined 
and a well-structured exercise allowing capture of all 
expected and unexpected adverse events and their 
grades and outcome. However, this is not necessa-
rily the case during daily routine clinical practice. And 
thus we expected challenges in extracting meaningful 
data on toxicity. For this reason we used dose delay 
for > 1 week (including discontinuation) and dose 
reduction due to adverse events as surrogates for 
serious toxicity. Dose delay was required in 13 (19.0%) 
and dose reduction in 9 (13.0%) patients. 16 (24.0%) 
patients had dose delay > 1 week and/or dose reduc-
tion. 6 (9.0%) patients required both dose reduction 
and dose delay > 1 week (including 2 regimen discon-
tinuations) due to toxicity. According to these findings 
and allowing for the limitations in the way we explored 
toxicity, tolerance to LBT in our patients is generally 
in line with what is expected and with the registration 
trial data.
Our patients are generally heavily pretreated. Most 
of them received hormonal therapy when appropri-
ate, adjuvant chemotherapy, palliative chemotherapy 
(1–3 lines) and T in either adjuvant and/or advanced 
settings. Despite heavy pretreatment and after failure 
of LBT, 20 (30.0%) patients received a subsequent line 
of chemotherapy (including L based in 7 patients). 
14 of them were evaluable for response. 5/14 (36.0%) 
achieved objective response. 7 (10.0%) patients re-
ceived a second subsequent line of chemotherapy 
(including L based in 1 patient). This observation indi-
cates that LBT does not limit feasibility of subsequent 
chemotherapy and its benefit.
CONCLUSION
In daily clinical practice, L is mostly combined 
with C for the treatment of women with A/MHER2+BC af-
ter progression on T. However, other L based combi-
nations are feasible and effective. In this setting, LBT 
produces meaningful tumor responses, PFS and OS are 
comparable to (and may exceed) those reported in clini-
cal trials. This benefit is likely to add to the survival gain 
achieved by prior and subsequent lines of therapy.
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